The Role of Probiotics in Antibiotic-Associated Diarrhea

Similar documents
Symptomspesifikke probiotikum. Linda Mulder, MSc. Vårseminaret 2014

Probiotics for the Treatment of Adult Gastrointestinal Disorders

Antibiotic-Associated Diarrhea, Clostridium difficile- Associated Diarrhea and Colitis

Clostridium Difficile Colitis. Presented by Mark Skains August 2003

Develop an understanding of the differential diagnosis of pseudomembranous colitis

Antimicrobial Stewardship for Hospital Acquired Infection Prevention: Focus on C. difficile infection

C. difficile Infections

Current and Future Applications of Probiotic Science

PROBIOTICS. Prof Kerryn Phelps 2012

PROBIOTICS. what they are and what they can do for you. A patient s guide from your doctor and

Migrene og mikroflora. Linda Mulder, MSc. Vårseminaret 2014

Probiotics for Gut Health

HYDROLYSATES IN EASY TO DIGEST FORMULAS

What Is Clostridium Difficile (C. Diff)? CLOSTRIDIUM DIFFICILE (C. DIFF)

growing problem By: Jena Cummins, Doctor of Pharmacy Candidate

C-Difficile Infection Control and Prevention Strategies

WARNING LETTER. According to its approved product labeling (PI) (in pertinent part, emphasis original):

Digestive System (continued) Digestive System. Stomach. Peptic Ulcer Disease

PHYSIOLOGY AND MAINTENANCE Vol. II Intestinal Microflora - Erkki Eerola, Wen Hua Ling

EVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze

Controlling intestinal microflora with BioHealth, MicroHealth and LactoHealth. Below illustration shows clearly the effects of unbalanced microflora

Treating Clostridium difficile infection (CDI) the second time around

Original Article:

TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER

Bacteriology. Mycology. Order Number: DOE DOB: July 17, 2006 Sex: M MRN: None. Rare. Negative. Brown. Negative *NG. Negative

Problems of the Digestive System

Vancomycin. Beta-lactams. Beta-lactams. Vancomycin (Glycopeptide) Rifamycins (rifampin) MID 4

The background behind Matula Herbal Formula

Treatment and Prevention Options for Clostridium difficile Infection (CDI)

Clostridium Difficile Colitis. Anton Sharapov, PGY 5

H. Pylori and Other GI Pathogens

Gloucestershire Hospitals

Clostridium difficile Not So Easy To Treat?

COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.

Ceftriaxone Therapy Vs. Ciprofloxacin In Treatment Of Typhoid Fever In Adult Patients.

Clostridium Difficile Colitis: Treatments, Guidelines, and Challenges

Clostridium difficileassociated of deaths. This has been the case for both hospital- and communityacquired

Treatments, Tapers, and Transplants: Guidelines and Options for Complicated C. diff Patients MIA A. TAORMINA, DO, FACOI

Eric Claassen, Immunologist Professor Erasmus Medical Center

Intra-abdominal abdominal Infections

Core Topic 2. The immune system and how vaccines work

Clostridium difficile Infection (CDI) Gail Bennett, RN, MSN, CIC

Learning Objectives. Introduction to Medical Careers. Vocabulary: Chapter 16 FACTS. Functions. Organs. Digestive System Chapter 16

Antidiarrheal Drugs. Causes of Diarrhea. Antidiarrheal Drugs

IBS. TomSult Sult, MD Patrick Hanaway, MD. Post Webinar Sept 21, 2011

Nursing college, Second stage Microbiology Dr.Nada Khazal K. Hendi L14: Hospital acquired infection, nosocomial infection

PRIORITY RESEARCH TOPICS

7 Reasons You Can t Eat the Foods You Love!

It s A Gut Feeling: Abdominal Pain in Children. David Deutsch, MD Pediatric Gastroenterology Rockford Health Physicians

APPENDIX B: UWHC SURGICAL ANTIMICROBIAL PROPHYLAXIS GUIDELINES

TITLE: CLOSTRIDIUM DIFFICILE INFECTION (CDI): GUIDELINES FOR THE MANAGEMENT OF ADULT PATIENTS

Aims of Nutritional Support in Oncology (Parenteral) Part 2

How antifungal drugs kill fungi and cure disease

Medical Nutrition Therapy for Upper Gastrointestinal Tract Disorders. By: Jalal Hejazi PhD, MSc.

3.0 Treatment of Infection

Approaches to Infection Control

{ Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta Analysis}

Clostridium difficile colitis

Probiotics (printer-friendly)

Second, updated edition Maija Saxelin, Ph.D. Published by Valio Ltd, R&D P.O. Box 30, FIN Helsinki, Finland Tel Fax

ESPEN Congress Florence 2008

Management of Extended Spectrum Beta- Lactamase (ESBL) Producing Enterobacteriaceae in health care settings

MDCH SHARP NHSN USERS CONFERENCE CALL Wednesday, March 25 th, 2015

COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR DERMATOLOGY

10. T and B cells are types of a. endocrine cells. c. lymphocytes. b. platelets. d. complement cells.

Antimicrobial Prophylaxis for Transrectal Prostate Biopsy: Organizational Recommendations. J. Stuart Wolf, Jr., M.D.

Appendix B: Provincial Case Definitions for Reportable Diseases

Tapered Withdrawal of a Proton Pump Inhibitor to Prevent Rebound Acid-Related Symptoms

Homeostatic Imbalances of the Digestive System

Clostridium Difficile colitismore virulent than ever ECHO- Sept 17, 2015

Inhibit terminal acid secretion from parietal cells by blocking H + /K + - ATPase pump

Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis

Original Article Clinical profile and antibiotics response in typhoid fever

Probiotics are live microorganisms

Prebiotics in Infant Nutrition

Running head: CLOSTRIDIUM DIFFICILE COLITIS 1. Clostridium Difficile Colitis: One Woman's Journey

Title: Vancomycin for C.difficile Pseudomembranous Colitis: Guidelines and a Clinical Effectiveness Review

Review of the evidence for H. Pylori treatment regimens. Dr Lennita Wannmacher

Inflammatory Bowel Disease. (Ulcerative Colitis and Crohn s Disease)

THE DIGESTIVE SYSTEM

Gastrointestinal tract barrier function

Supplemental Material CBE Life Sciences Education. Su et al.

BioGaia a healthcare company working with probiotics

Equine Equine Diarrhea Diarrhea Diarrhea in the Horse: Salmonella and Other Infections Introduction Clinical Signs

CONSUMERS UNION POLICY BRIEF HOSPITAL-ACQUIRED C. DIFFICILE INFECTIONS (CDI) 11-08

Ingredients. Triphase Pharmaceuticals Pvt Ltd

PACKAGE LEAFLET. CLINDAMYCIN capsules Clidamycin. One capsule of 75 mg contains 75 mg Clindamycin (as hydrochloride).

Chapter 16: Innate Immunity

BioGaia a healthcare company working with probiotics

BioGaia a healthcare company working with probiotics

BioGaia a healthcare company working with probiotics

Probiotics May Prevent and Treat Clostridium Difficile By Mary Rodavich, MS, RD, LDN. Suggested CDR Learning Codes: 3100, 4040, 5220, 5270; Level 2

Chronic Diarrhea in Children

Lecture Outline. Quinolones

Chapter 3. Immunity and how vaccines work

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal

Fecal Microbiota Transplantation for Clostridium Difficile Infection: A Systematic Review of the Evidence

Definition: What is the Microbiome- A Big Picture

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Lymph capillaries, Lymphatic collecting vessels, Valves, Lymph Duct, Lymph node, Vein

Transcription:

The Role of Probiotics in Antibiotic-Associated Diarrhea Elena Lionetti, MD, PhD Department of Paediatrics University of Catania, Italy.

The Gut Microbiota 1. More than 400 species of bacteria inhabit the human gut and perform functions essentials for our survive. 2. Colonization resistance refers to the "limiting action" of the normal flora on colonization of the bowel by exogenous as well as endogenous potentially pathogenic microorganisms. (Plos Biol 2008; 6:2383-400)

Antibiotic side effects Nausea Abdominal distension Headache Taste disturbance Abdominal pain Vomiting Diarrhea Antibiotic-Associated Diarrhea (AAD) is defined as otherwise unexplained diarrhea that occurs in association with the administration of antibiotics. (NEJM 2002; 346:334-9)

Incidence of the problem 11 Hospitalization, Immunosuppression, Early age, Broad-spectrum antibiotic use Combined antibiotic therapy Prolonged antibiotic therapy Risk factors Incidence 30 40 0 10 20 30 40 % (JPGN 2003; 37:2-3)

Spectrum of clinical finding Nuisance diarrhoea Abdominal pain and cramps Fever (leukocitosis & hypoalbunimia) Colitis (C. Difficile) (J Pediatr 2006;149:367-72)

Any antibiotic can cause AAD macrolide fluoroquinolone tetracycline 5 5 5 ampicillin 10 3 rd gen cephalosporins 20 amoxy-clavulanate 25 clindamycin 30 0 10 20 30 40 % (NEJM 2002; 346:334-9)

Mechanism of AAD 100% Metabolic consequences of altered flora: (reduction of the concentration of intestinal anaerobes) 80% 60% 40% 20% 0% a) Reduced digestion of CHO and increased colonic osmotic load leading to osmotic diarrhoea; b) Reduced breakdown of primary bile acids, which are potent colonic secretory agents. Overgrowth of other enteric pathogens: a) Salmonella; b) Clostridium perdingens A; c) Staphilococcus Aureus; d) Candida Albicans. Clostridium difficile: a) Colonisation; b) Toxins; (J Clin Gastroenterol 2008; 42:58 63)

Costs AAD is responsible for: a) longer hospital stay (8 days on average); b) higher cost of care ($2000-4000 per stay); c) 5 fold increase in the incidence of other nosocomial infections; d) 3 fold increase in mortality (ranging from 0.7% to 38%). There is thus considerable interest in measures capable of prevention or amelioration of this condition. (Best Pract Res Clin Gastroenterol 2003; 17:775; Dig Dis 1998; 10:292)

Have probiotics a role in AAD?

Mechanism of action of Probiotics Non immunological 1. Production of antimicrobial substances (lactic/aceric acid, H 2 O 2 ; reuterin) 2. Inhibition of epithelial and mucosal adherence of pathogens (physical blocking of pathogen adhesion receptors, secretion of antibacterial molecules, stimulation of the secretion of antimicrobial substances such as defensin) 3. Competition for nutrients 4. Stabilization of the barrier function of the gut epithelium (restoring paracellular permeability, increasing mucus production) Immunological (Dig Liver Dis 2002:78-80)

Mechanism of action of Probiotics Non immunological 1. Production of antimicrobial substances (lactic/aceric acid, H 2 O 2 ; reuterin) 2. Inhibition of epithelial and mucosal adherence of pathogens (physical blocking of pathogen adhesion receptors, secretion of antibacterial molecules, stimulation of the secretion of antimicrobial substances such as defensin) 3. Competition for nutrients 4. Stabilization the barrier function of the gut epithelium (restoring paracellular permeability, increasing mucus production) Immunological 1. Stimulating cytokine production; 2. Enhancing the phagocytic capacity (of polymorphonuclear cells and macrophages); 3. Prevention of apoptosis (prolonged survival of enterocytes); 4. Stimulation of immunity (especially the IgA response) 5. Enhancing specific antibody responses to pathogenic organisms (Dig Liver Dis 2002:78-80)

From bench to bedsides

From bench to bedsides All randomized paediatric controlled trials where a specified probiotic agent has been compared to placebo (10 RCT identified) Objective was to assess the effect of probiotics for prevention of paediatric antibiotic associated diarrhea

Effects of probiotics in children with AAD 1 st Outcome Incidence of diarrhea

Effects of probiotics in children with AAD Probiotics are effective for preventing AAD (-11%)

Effects of probiotics in children with AAD 2 nd Outcome Mean duration of diarrhea

Effects of probiotics in children with AAD Probiotics decreased the mean duration of diarrhea by ¾ of a day

Effects of probiotics in children with AAD 3 rd Outcome Probiotic strain

Effects of probiotics in children with AAD The effect is strain dependent (LGG and S. boulardii best)

Effects of probiotics in children with AAD 4 th Outcome Probiotic dose

Effects of probiotics in children with AAD 5 billion CFU probiotic/day 5 billion CFU probiotic/day The effect is dose dependent

Effects of probiotics in children with AAD 5 th Outcome Antibiotic class

Effects of probiotics in children with AAD Placebo Macrolides 5.5% 11.4% p=ns Probiotic Cephalosporins 3.9% 14.3% p=ns Beta-lactams penicillins 5.5% 25% p<0.001 0 5 10 15 20 25 30 % Best preventive effect if co-administered with penicillins

Effects of probiotics in children with AAD 6 th Outcome Safety

Effects of probiotics in children with AAD No statistically significant difference in the incidence of adverse events between treatment and control

After the Cochrane. Bifidobacterium longum PL03, Lactobacillus rhamnosus KL53A, and Lactobacillus plantarum PL02 in the prevention of antibiotic-associated diarrhea in children: a randomized controlled pilot trial. Szyma ski H, Arma ska M, Kowalska-Duplaga K, Szajewska H. The administration of the 3 probiotics did not significantly alter the rate of diarrhea, although it reduced the frequency of loose stools per day. L. rhamnosus to children receiving antibiotics reduced the risk of diarrhea. L. GG did not significantly improve the antibiotic side effects. (Digestion 2008; 78:13-7 - Aliment Pharmacol Ther 2008; 28:154 - JPGN 2009;48:431)

To eradicate HP we need PPI + Amoxy + Clarithromycin Amoxy + Tinidazole Amoxy + Metronidazole + Clarithromycin Amoxy + Clarithromycin + Tinidazole for 7, 10 or 15 days (Gut 2007; 56:772)

Our experience with L. reuteri 55730 (Alim Pharm Therap 2006; 24:1461-8)

L. reuteri 55730 and antibiotic associated side effects Placebo 1 cps/die *Gastrointestinal Symptom Rating Scale. It comprises 15 items describing abdominal pain gastro-esophageal reflux, abdominal distension, diarrhea and constipation. (Dig Dis Sci. 1988;33:129) 40 children R D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 Eradicating Therapy D11 D12 D13 D14 D15 D16 D17 D18 D19 D20 Follow-up Reuterin (10 8 CFU ) 1 cps/die (Lionetti E. Alim Pharm Therap 2006; 24:1461-8)

L. reuteri 55730 and antibiotic associated side effects In all probiotic supplemented children, as compared to those receiving placebo, there was a significant reduction in the GSRS score during eradicating therapy, which became markedly evident at the end of follow-up. 16 p<0.005 14 p<0.008 12 10 GSRS 8 6 4 2 0-2 Day 0 Entry Day 10 End of Tx Day 20 Follow-up (Lionetti E. Alim Pharm Therap 2006; 24:1461-8)

L. reuteri 55730 and antibiotic associated side effects 60 50 on-tx 45 Children receveing L. reuteri v. placebo complained less frequently of epigastric pain during therapy (15% vs. 45%; p<0.03) and abdominal distension (0% vs. 25%; p<0.02), diarrhea (15% vs. 45%; p<0.04), eructation (5% vs. 35%; p< 0.04) and halitosis (5% vs. 35%; p< 0.04) thereafter. 45 40 35 35 30 25 20 15 15 10 0 5 5 0 Epig Pain Abd Dist Diarrhea Eructation Halitosis (Lionetti E. Alim Pharm Therap 2006; 24:1461-8)

L. reuteri 55730 and antibiotic associated side effects 100 80 85 75 50 No adverse event 25 0 Tx + placebo Tx + reuteri No differences in adherence to treatment schedules (97% in both groups) and H. pylori eradication rates (85% vs. 80%; p= NS). (Lionetti E. Alim Pharm Therap 2006; 24:1461-8)

What next 1. Probiotics are a promising option to prevent or ameliorate AAD. 2. Specific strains at high doses should be used. 3. For every 10 patients treated with antibiotics 1 will not develop diarrhea if also receiving probiotics. 4. Future studies are needed to address the cost-effectiveness of this primary prophylaxis. 5. The judicious use of antibiotics remains the best method of preventing antibiotic associated side-effects.